home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Defects In Iron Metabolism Cause Some Neurodegenerative Disorders

 
  August, 13 2001 3:20
your information resource in human molecular genetics
 
     
Nerves of…iron?

As we age, iron accumulates in various regions of our brains, and an excess of iron is usually found in the parts of the brain that degenerate in disorders such as Parkinson and Alzheimer diseases. Because some level of higher-than-normal iron concentrations tends to accompany the aging process, it is difficult to say whether there is any pathological effect produced by excess iron in brain.

Work by two groups of researchers Nature Genetics (Vol. 28, pp. 327-334) has now revealed that defects in iron metabolism do in fact cause some neurodegenerative disorders. John Burn (of the Institute of Human Genetics) and colleagues found that one of the two genes required to make the ferritin protein-which acts as a storage depot for iron-is mutated in a number of individuals suffering from neurodegeneration. The mutation seems to make the protein less stable, and so perhaps less iron is stored in the ferritin complex and more iron accumulates.
In a second study, of a population of Amish individuals, Susan Hayflick (of Oregon Health and Sciences University) and colleagues find that a condition called Hallervorden-Spatz syndrome-characterized by the most profound accumulations of excess iron in the brain of any neurodegenerative disorder-results from mutation of another gene, PANK2. This gene encodes a factor, expressed specifically in the brain, that may modulate iron levels by a secondary mechanism involving the amino acid cysteine.

In an accompanying News & Views article, Tracey Roualt (of the National Institute of Child Health and Human Development) describes how these findings correlate with those obtained from mouse studies, and explains how they may lead to new insights into neurodegenerative diseases and the design of specific treatments.

CONTACTS:
Dr. Susan J. Hayflick
Oregon Health Science University
Dept of Molecular & Medical Genetics
Portland, Oregon, USA
Telephone: +1 503 494 6866
Fax: +1 503 494 4411
e-mail: hayflick@ohsu.edu

Dr. John Burn
University Newcastle-upon-Tyne
Division of Human Genetics
Newcastle-upon-Tyne, UK
Telephone: +44 191 222 8869
Fax: +44 191 222 7143
e-mail: john.burn@newcastle.ac.uk

(C) Nature Genetics press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.